Endothelin in myocardial ischaemia and reperfusion

Cardiovascular Research

Volumn 33, Issue 3, 1997, Pages 518-526

  Pernow, John ^a   Wang, Qing Dong ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antagonists; Endothelin; Myocardial ischemia; Receptors; Reperfusion; Vasoconstriction

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SWINE; VASOCONSTRICTION;

ENDOTHELIN-1; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDES, CYCLIC;

EID: 0031043781     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(96)00265-9     Document Type: Review

References (71)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
2. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
3. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family, three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867.
4. Resink TJ, Hahn AW, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 1990:168:1303-1310.
5. Suzuki T, Kumazaki T, Mitsui Y. Endothelin 1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 1993;191:823-830.
6. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994;46:137-142.
7. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin 1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993:191:1081-1088.
8. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 1993:72:526-538.
9. Davenport AP, O'Reilly G, Kuc RE. Endothelin ET(a) and ET(b) mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ET(a) subtype. Br J Pharmacol 1995:114:1110-1116.
10. Karne H, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993:268:19126-19133.
11. Sugden PH, Bogoyevitch MA. Endothelin-1-dependent signaling pathways in the myocardium. Trends Cardiovasc Med 1996;6:87-94.
12. Hasdai D, Kornowski R. Battler A. Endothelin and myocardial ischemia. Cardiovasc Drugs Ther 1994;8:589-599.
13. Grover GJ, Sleph PG, Fox M, Trippodo NC. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J Pharmacol Exp Ther 1992:263:1074-1082.
14. B) mediate vasoconstriction in the perfused rat heart. J Cardiovasc Pharmacol 1993:22(suppl 8):S248-S251.
15. Wang Q-D, Li X-S, Pernow J. Characterization of endothelin-1-induced vascular effects in the rat heart by using endothelin receptor antagonists. Eur J Pharmacol 1994:271:25-30.
16. Nichols AJ, Koster PF. Ohlstein EH. The effect of diltiazem on the haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dog. Br J Pharmacol 1990:99:597-601.
17. Wang Q-D. Hemsén A. Li X-S, Lundberg JM, Uriuda Y. Pernow J. Local overflow and enhanced tissue content of endothelin following myocardial ischaemia and reperfusion in the pig: modulation by L-arginine. Cardiovasc Res 1995;29:44-49.
18. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary vasoconstrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996;94:2077-2082.
19. Garjani A, Wainwright CL, Zeitlin IJ, Wilson C, Slee S-J. Effects of endothelin-1 and the ETA-receptor antagonist BQ123, on ischemic arrythmias in anesthetized rats. J Cardiovasc Pharmacol 1995;25:634-642.
20. Miyauchi T, Yanagisawa M, Tomizawa T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989;ii:53-54
21. Yasuda M, Kohno M, Thara A, et al. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J 1990;119:801-806.
22. Naruse M, Kawana M, Hifumi S. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential hypertension and ischemic heart disease. J Cardiovasc Pharmacol 1991;17(suppl 7):S471-S474.
23. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 1993;125:667-672.
24. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after myocardial infarction. Circulation 1994;89:1573-1579.
25. Qiu S, Théroux P. Marcil M, Solymoss BC. Plasma endothelin-1 levels in stable and unstable angina. Cardiology 1993;82:12-18.
26. Wieczorek I, Haynes WG, Webb DJ, Ludlam CA, Fox KAA. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994;72:436-441.
27. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Endothelin in myocardial infarction. Nature 1990;344:114.
28. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991;69:370-377.
29. Tsuji S, Sawamura A, Watanabe H, Takihara K, Park S-E, Azuma J. Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci 1991;48:1745-1749.
30. Tønnessen T, Naess PA, Kirkebøen KA, Offstad J, Ilebekk A, Christensen G. Release of endothelin from the porcine heart after short term coronary artery occlusion. Cardiovasc Res 1993;27:1482-1485.
31. Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987;21:737-746.
32. Hearse DJ, Muller CA, Fukanami M, Kudoh Y, Opie LH, Yellon DM. Regional myocardial ischemia: Characterization of temporal, transmural and lateral flow interfaces in the porcine heart. Can J Cardiol 1986;2:48-61.
33. Velasco CE, Turner M, Inagami T, et al. Reperfusion enhances the local release of endothelin after regional myocardial ischemia. Am Heart J 1994;128:441-451.
34. Franco-Cereceda A, Ericsson A, Sellei P, Vaage G, Valen G, Lundberg JM. Endothelin release at reperfusion of the porcine ischaemic heart in relation to noradrenaline and neuropeptide Y. Acta Physiol Scand 1994;151:541-543.
35. Miyauchi T, Doi T, Suzuki N, et al. Plasma endothelin-1 concentrations in the coronary sinus in dogs with artificially induced myocardial infarction. Peptides 1992;13:1013-1015.
36. Tomoda H. Coronary thrombosis and endothelin-1 release. Angiology 1993;44:441-446.
37. A receptor-mediated coronary vasoconstriction following coronary thrombosis and thrombolysis in the pig. J Cardiovasc Pharmacol 1995;26:770-776.
38. Tønnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 1995;76:767-772.
39. Saito T, Furshimi E, Abe T. Augmented contractile response to endothelin and blunted endothelium-dependent relaxation in post-ischemic reperfused coronary arteries. Jpn Circ J 1992;56:657-670.
40. Neubauer S, Zimmermann S, Hirsch A, et al. Effects of endothelin-1 in the isolated heart in ischemia/reperfusion and hypoxia/reoxygenation injury. J Moll Cell Cardiol 1991;23:1397-1409.
41. Watts JA, Chapat S, Johnson DE, Janis RA. Effects of nisodipine upon vasoconstrictor responses and binding of endothelin-1 in ischemic and reperfused rat hearts. J Cardiovasc Pharmacol 1992;19:929-936.
42. Thompson M, Westwick J, Woodward B. Responses to endothelin-1, -2, and -3 and sarafotoxin 6c after ischemia/reperfusion in isolated perfused rat heart: role of vasodilator loss. J Cardiovasc Pharmacol 1995;25:156-162.
43. 125I-labeled endothelin-1 binding in rat cardiac membranes. Am J Physiol 1990;258 :H829-H835.
44. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993;27:1613-1618.
45. Wang Q-D, Li X-S, Lundberg JM, Pernow J. Protective effect of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 1995;29:805-812.
46. Hagar JM, Geda M. Endogenous endothelin increases myocardial infarct size. Circulation 1995:92(suppl I):I-455.
47. B receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995; 114:949-954.
48. A receptor antagonist reduces myocardial infarction induced by coronary occlusion and reperfusion in the rat. Pharmacology 1994;49:319-324.
49. B antagonist. Br J Pharmacol 1994;113:869-876.
50. Li X-S, Wang Q-D, Pernow J. Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischemia/reperfusion in the rat. Eur J Pharmacol 1995;283:161-168.
51. Han H, Neubauer B, B, Ertl G. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart - Attenuation of ischemic injury by the endothelin antagonists BQ123 and BQ610. J Moll Cell Cardiol 1995;27:761-766.
52. Illing B, Horn M, Han H, et al. Protective effect of the specific endothelin-1 antagonist BQ610 on mechanical function and energy metabolism during ischemia/reperfusion injury in isolated perfused rat hearts. J Cardiovasc Pharmacol 1996;27:487-494.
53. Hiramatsu T, Forbess J, Miura T, Roth SJ, Cioffi MA, Mayer JE. Effects of endothelin-1 and endothelin-A receptor antagonist on recovery after hypothermic cardioplegic ischemia in neonatal lamb hearts. Circulation 1995;92(suppl II):400-404.
54. Tsao PS, Aoki N, Lefer DJ, Johnson G, Lefer AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990;82:1402-1412.
55. Hagar JM. Endogenous endothelin-1 impairs endothelium-dependent relaxation after myocardial ischemia and reperfusion. Am J Physiol 1994;267:H1833-H1841.
56. Krause SM, Lynch JJ, Stabilito II, Woltmann RF. Intravenous administration of the endothelin-1 antagonist BQ-123 does not ameliorate myocardial ischaemic injury following acute coronary artery occlusion in the dog. Cardiovasc Res 1994;28:1672-1678.
57. A receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol 1994;112:75-80.
58. Dagassan PH, Breu M, Clozel M, Clozel JP. Role of endothelin during reperfusion after ischaemia in isolated perfused rat heart. J Cardiovasc Pharmacol 1994;24:867-874.
59. Donckier J, Hanet C, Stoleru L, et al. Effects of endothelin-1 at pathophysiologic concentrations on coronary perfusion and mechanical function of normal and postischemic myocardium. J Cardiovasc Pharmacol 1994;23:212-219.
60. Sargent CA, Liu ECK, Chao C, Webb ML, Grover GJ. Role of endothelin receptor subtype B (ET-B) in myocardial ischemia. Life Sci 1994;55:1833-1844.
61. Hide EJ, Piper J, Thiemermann C. Endothelin-1-induced reduction of myocardial infarct size by activation of ATP-sensitive potassium channels in a rabbit model of myocardial ischaemia and reperfusion. Br J Pharmacol 1995;116:2597-2602.
62. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 1993;33:71-90.
63. Wang P, Gallagher KP, Downey JM, Cohen MV. Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. J Moll Cell Cardiol 1996;28:579-588.
64. Hansen PR. Myocardial reperfusion injury: experimental evidence and clinical relevance. Eur Heart J 1995;16:734-740.
65. Ambrosio G, Weisman HF, Mansini JA, Becker JC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989;80:1846-1861.
66. Gómez-Garre D, Guerra M, González E, et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet activating factor. Eur J Pharmacol 1992;224:167-172.
67. Ishida K, Takeshige K, Minakami S. Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanin. Biochem Biophys Res Commun 1990;173:496-500.
68. López-Farré A, Riesco A, Espinosa G, et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation 1993;88:1166-1171.
69. Galron R, Bdolah A, Kloog Y, Sokolovsky M. Endothelin/sarafotoxin receptor induced phosphoinositide turnover: Effects of pertussis and cholera toxins and of phorbol esters. Biochem Biophys Res Commun 1990;171:949-954.
70. Nayler WG. Calcium antagonists and the ischaemic myocardium. Int J Cardiol 1987:15:267.
71. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994:128:1-6.